Home People Barry Borlaug – Biography, Age, Medical Education, Career & Net Worth

Barry Borlaug – Biography, Age, Medical Education, Career & Net Worth

Barry Borlaug (born January 1972) is a board-certified American cardiologist in Rochester, Minnesota. He subspecializes in heart failure and transplantation.

Borlaug is a Professor of Medicine, Department of Cardiovascular Medicine, The Mayo Clinic.

Barry Borlaug

Barry Borlaug Facts

  • Full Name: Barry A Borlaug
  • Age: 51 years old
  • Date of Birth: January 1972
  • Occupation: Cardiologist
  • Nationality: American

Barry Borlaug Medical School & Residency

  • Johns Hopkins University – Fellowship, Cardiovascular Disease, 2002-2005
  • Brigham and Women’s Hospital – Residency, Internal Medicine, 1999-2002
  • University of Wisconsin School of Medicine and Public Health – Medical School

Barry Borlaug Career

Dr. Barry A. Borlaug’s research focuses on the mechanisms, diagnosis, and therapy of heart failure. Dr. Borlaug is especially interested in heart failure with maintained ejection fraction, which accounts for almost half of the heart failure population but has no established treatment.

Dr. Borlaug is now conducting a number of clinical investigations and therapy studies to uncover novel techniques, devices, and treatments for heart failure patients.

Certifications & Licensure

  • American Board of Internal Medicine – Certified in Advanced Heart Failure and Transplant Cardiology
  • PA State Medical License – Active through 2006
  • MN State Medical License – Active through 2023
  • WI State Medical License – Active through 2017

Hospital Affiliations

  • Mayo Clinic – Rochester
  • Mayo Clinic Hospital, Saint Marys Campus

Specialty Expertise

Barry A Borlaug has the following 20 areas of expertise

  • Acute Venous Embolism Thrombosis
  • Angina and Acute Coronary Syndrome
  • Aortic Aneurysm
  • Aortic Dissection
  • Aortic Ectasia
  • Aortic Stenosis
  • Aortic Valve Disease
  • Aortic Valve Regurgitation
  • Arrhythmias
  • Atrial Fibrillation
  • Cardiac Catheterization (incl. Coronary Angiography)
  • Cardiac Electrophysiology
  • Cardiac Imaging
  • Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
  • Cardiac Myocardial Perfusion Imaging
  • Cardiovascular Stress Test
  • Cardioversion, Elective
  • Cardioverter-Defibrillator or Pacemaker Insertion, Removal or Repair
  • Chest CT (incl. Heart and Lungs)
  • Coronary Angioplasty, Atherectomy and Stent

Insurance Accepted

  • Aetna Choice POS II
  • Aetna Managed Choice POS Open Access
  • Aetna Signature Administrators PPO
  • Aexcel PPO
  • Anthem Blue Access PPO
  • Anthem Blue Preferred HMO
  • Anthem Blue Preferred Plus POS
  • BCBS Blue Card PPO
  • Blue Cross Aware
  • CIGNA Open Access Plus
  • HealthPartners MN CareChoices
  • HealthPartners MN CentraChoice
  • HealthPartners MN Distinctions II
  • Humana Choice POS
  • Humana ChoiceCare Network PPO
  • Medica with Mayo Clinic
  • Multiplan PPO
  • Preferred One PPO
  • UHC Choice Plus POS
  • UHC Medica Choice
  • UHC Options PPO
  • Wellmark Blue PPO
  • WPS Group

Location & Contact Information

Mayo Clinic
200 First Street SW
Rochester, MN 55905
(507) 299-0755

Expert Publications

Data provided by the National Library of Medicine

  • Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy.
  • Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans.
  • Mechanisms of diastolic dysfunction in heart failure.
  • Estimation of central pressure augmentation using automated radial artery tonometry.
  • Ventricular-vascular interaction in heart failure.
  • Severe heart failure in the setting of relatively mild mitral stenosis: the role of invasive hemodynamic assessment.
  • Treatment of heart failure with preserved ejection fraction.
  • Invasive hemodynamic assessment in heart failure.
  • Caveat medicus! Pulmonary hypertension in the elderly: a word of caution.
  • Heart failure with preserved ejection fraction: pathophysiology and emerging therapies.
  • Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.
  • Sex, load, and relaxation: are women more susceptible to load-dependent diastolic dysfunction?
  • Invasive hemodynamic assessment in heart failure.
  • Discerning pulmonary venous from pulmonary arterial hypertension without the help of a catheter.
  • Ventricular-vascular interaction in heart failure.
  • Clinical Trials
  • Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in HFpEF (INABLE-Training)
  • Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure
  • Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.

Barry Borlaug Net Worth

Barry Borlaug has an estimated net worth of $6 million.



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.